Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9445656 | 0.88 | SMN1; SMN2 (0.63) | SMN1; SMN2CYP19A1KMT2AHTTGAA | |
| SCHEMBL6696208 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2CYP19A1KMT2AMEN1HTT | |
| SCHEMBL22163991 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP19A1KMT2AMEN1HTT | |
| SCHEMBL396053 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP19A1KMT2AMEN1HTT | |
| SCHEMBL9523590 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP19A1KMT2AMEN1HTT | |
| SCHEMBL30168169 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2CYP19A1KMT2AHTTGAA | |
| SCHEMBL7122790 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2CYP19A1KMT2AHTTGAA | |
| SCHEMBL915213 | 0.78 | MEN1 (0.64) | SMN1; SMN2KMT2AMEN1HTTLMNA | |
| SCHEMBL4326710 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2CYP19A1KMT2AHTTGAA | |
| SCHEMBL427418 | 0.78 | HTT (0.67) | SMN1; SMN2KMT2AMEN1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214798-A1 | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation | HU, LONGQIN | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214798-A1 | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation | MKI67, NME2, NTPCR | SMN1; SMN2 3095/4885CYP19A1 940/4885KMT2A 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.